US 12,357,711 B2
PSMA binding dual mode radiotracer and therapeutic
Alexander Josef Wurzer, Munich (DE); Hans-Jürgen Wester, Ilmmünster (DE); and Matthias Johannes Eiber, Vaterstetten (DE)
Assigned to Technische Universität München, Munich (DE); and TECHNISCHE UNIVERSITÄT MÜNCHEN— KLINIKUM RECHTS DER ISAR, Munich (DE)
Appl. No. 17/426,962
Filed by Technische Universität München, Munich (DE); and Technische Universität München—Klinikum Rechts der Isar, Munich (DE)
PCT Filed Jan. 30, 2020, PCT No. PCT/EP2020/052248
§ 371(c)(1), (2) Date Jul. 29, 2021,
PCT Pub. No. WO2020/157177, PCT Pub. Date Aug. 6, 2020.
Claims priority of application No. 19154500 (EP), filed on Jan. 30, 2019.
Prior Publication US 2022/0096668 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/04 (2006.01); A61P 35/00 (2006.01); C07B 59/00 (2006.01)
CPC A61K 51/0406 (2013.01) [A61K 51/0497 (2013.01); A61P 35/00 (2018.01); C07B 59/008 (2013.01); C07B 2200/05 (2013.01)] 14 Claims
 
1. The compound according to formula (V):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein F is optionally 18F.